<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health</h1>

    <table>
      <tr><th>Ticker</th><td>ELAB</td></tr>
      <tr><th>Float</th><td>1.1 M</td></tr>
      <tr><th>IO</th><td>0.05%</td></tr>
      <tr><th>MC</th><td>2.9 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>PMGC Holdings' subsidiary NorthStrive Biosciences executed a definitive, exclusive, royalty-bearing and sublicensable worldwide (ex-Korea) license with Modulant Biosciences for NorthStrive's EL-22 and EL-32 programs. The license grants Modulant rights to develop, manufacture, obtain regulatory approvals for, and commercialize products derived from EL-22 and EL-32 for non-human animal health uses (including feed additives). The agreement covers issued patents, pending applications and related know-how; Modulant is responsible for development, manufacturing and commercialization using commercially reasonable efforts. The license excludes human pharmaceutical/clinical applications. NorthStrive and Modulant will share ownership of improvements; Modulant may grant sublicenses. No financial terms were disclosed. The release notes risks that Modulant may not successfully develop or commercialize products or obtain regulatory approvals.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Definitive exclusive license executed, converting prior term sheet into a binding agreement</li><li>Worldwide license (excluding Republic of Korea) grants Modulant rights to develop, manufacture and commercialize animal-health products</li><li>Royalty-bearing and sublicensable structure creates potential ongoing revenue for NorthStrive/PMGC</li><li>Agreement covers issued patents, pending applications and proprietary know-how</li><li>Modulant assumes responsibility for development, manufacturing, regulatory and commercialization activities</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>No financial consideration or payment amounts disclosed in the press release</li><li>License expressly excludes human pharmaceutical/clinical applications, limiting potential markets</li><li>Success depends on Modulant's ability to develop products, obtain regulatory approvals and achieve market acceptance</li><li>Agreement excludes the Republic of Korea, reducing geographic scope</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/ea6c30ea-3d42-4071-b6fd-94f676bbd8f7" target="_blank">Original Article</a>
    </div>

    <div class="small">ELAB â€¢ TradersLink AI News</div>
  </div>
</body>
</html>